Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) : vimarsana.com

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms



ADZYNMA is the First and Only Recombinant ADAMTS13 Enzyme...

Related Keywords

United States , Japan , Japanese , Yasushi Kajii , Thromb Haemost , Kremer Hovinga , Van Dorland , European Medicines Agency , Japan Ministry Of Health , Takeda Pharmaceutical Company Limited , Exchange Commission , Drug Administration , Japanese Ministry Of Health , Takeda Pharmaceuticals United Statesa Inc , Japanese Ministry , Orphan Drug Designation , Product Overview , Specific Populations , Takeda Pharmaceuticals United Statesa , Prescribing Information , Annual Report , Accessed March , Rev Dis , Thrombotic Thrombocytopenic , Markets ,